Ciprofloxacin HCl 0.3 % Ophthalmic Solution
RxNorm 309307
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 309307 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ciprofloxacin HCl 0.3 % Ophthalmic Solution.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Ciprofloxacin 3 mg/ML Ophthalmic Solution
(Atom ID: 12339246)
PTPrescribable
Designated preferred name (PT):
Ciprofloxacin (as ciprofloxacin hydrochloride) 3 mg/mL eye drops
(Atom ID: 10296253)
SYPrescribable
Synonym (SY):
Ciprofloxacin 0.3 % Ophthalmic Solution
(Atom ID: 3286266)
SYPrescribable
Synonym (SY):
Ciprofloxacin 3 mg/ML (as ciprofloxacin hydrochloride 3.5 mg/ML) Ophthalmic Solution
(Atom ID: 5948487)
PSNPrescribable
Prescribable Name (PSN):
Ciprofloxacin HCl 0.3 % Ophthalmic Solution
(Atom ID: 6812298)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely ciprofloxacin (as ciprofloxacin hydrochloride) 3 mg/1 mL conventional release eye drops (clinical drug)
(Atom ID: 10310701)
Patient Education
Ciprofloxacin Ophthalmic
Ciprofloxacin ophthalmic solution is used to treat bacterial infections of the eye including conjunctivitis (pinkeye; infection of the membrane that covers the outside of the eyeball and the inside of the eyelid) and corneal ulcers (infection and loss of tissue in the clear front part of the eye). Ciprofloxacin ophthalmic ointment is used to treat conjunctivitis. Ciprofloxacin is in a class of antibiotics called fluoroquinolones. It works by killing the bacteria that cause infection.
[Learn More]
* Please review the disclaimer below.